Health AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline December 6, 2022
Biotechnology Editas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease December 6, 2022
Health Emergent BioSolutions Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-the-Counter NARCAN® (naloxone HCl) Nasal Spray December 6, 2022
Health AbbVie to Showcase Migraine Portfolio and Pipeline During the 16th European Headache Federation Congress December 6, 2022
Search
Health
